) databases. Abstracts were scrutinized, and full articles were analyzed. The literature retrieval was performed by two independent authors. And no language or date restrictions were found in literature collection. Results: Sixteen cohort studies, covering 4393 WT and 916 BIM deletion patients were included. Overall, BIM deletion polymorphism was associated with significantly shorter progression-free survival (PFS) and slightly shorter overall survival (OS), compared to the WT group. Moreover, patients with BIM deletion polymorphism showed significantly inferior response to EGFR TKIs. Background: Lung cancer is the leading cause of cancer-related death worldwide and metastatic dissemination of lung cancer cells represents a significant clinical obstacle to cure the disease. Aberrant DNA methylation represses gene expression and correlates with cell proliferation, angiogenesis, invasion and metastasis. Many DNA methylation markers have already been used in the early detection of lung cancer. The role of DNA methylation in lung cancer metastasis remains poorly understood and no satisfied marker predicting metastasis were found up to date. We will try to screen out usable methylation markers to improve our diagnosis for metastasis in lung cancer. Method: Scientific literature databases were exhaustively searched to retrieve published studies relevant to DNA methylation and NSCLC metastasis. Retrieved studies published in English and Chinese languages were screened according to the stringent predefined inclusion and exclusion criteria, and high quality studies were selected for further analysis. Genes were screened and sorted for further validation. Results: A total of 45 published studies were selected in the present analysis. 23 genes or microRNAs were studied in the relationship between methylation and tumor metastasis. The genes include metastatic genes, metastasis suppressor genes, EMT-related genes, microRNAs and noncoding RNA. The methylation rate of these genes and tumor metastasis were studied. Genes with intensive research include P16, Rassf1, DAPK, HOXA5, SOX9, MALAT1 and microRNAs such as mir-182, mir-139. mir-224. No further studies were regarded in the prediction value of these markers in serum and CTC in lung cancer metastasis. These markers might be validated in metastasis prediction in further studies. Conclusion: Our analysis results reveal that methylation might be associated with tumor metastasis and poor prognosis in NSCLC patients, and might be good markers in liquid biopsy for early detection of lung cancer metastasis.
words: "BIM" or "BCL-2-like 11" or "BCL2-like 11" or "BCL-2 like 11" AND "polymorphism" AND "lung cancer". We collected data from the all full-published English papers, not any meeting or conference abstract. A thorough literature search was undertaken using the following databases: PubMed (http://www.ncbi.nlm.nih. gov), Embase (http://www.embase.com), and Science Direct (http://www.sciencedirect.com) databases. Abstracts were scrutinized, and full articles were analyzed. The literature retrieval was performed by two independent authors. And no language or date restrictions were found in literature collection. Results: Sixteen cohort studies, covering 4393 WT and 916 BIM deletion patients were included. Overall, BIM deletion polymorphism was associated with significantly shorter progression-free survival (PFS) and slightly shorter overall survival (OS), compared to the WT group. Moreover, patients with BIM deletion polymorphism showed significantly inferior response to EGFR TKIs. Background: Lung cancer is the leading cause of cancer-related death worldwide and metastatic dissemination of lung cancer cells represents a significant clinical obstacle to cure the disease. Aberrant DNA methylation represses gene expression and correlates with cell proliferation, angiogenesis, invasion and metastasis. Many DNA methylation markers have already been used in the early detection of lung cancer. The role of DNA methylation in lung cancer metastasis remains poorly understood and no satisfied marker predicting metastasis were found up to date. We will try to screen out usable methylation markers to improve our diagnosis for metastasis in lung cancer. Method: Scientific literature databases were exhaustively searched to retrieve published studies relevant to DNA methylation and NSCLC metastasis. Retrieved studies published in English and Chinese languages were screened according to the stringent predefined inclusion and exclusion criteria, and high quality studies were selected for further analysis. Genes were screened and sorted for further validation. Results: A total of 45 published studies were selected in the present analysis. 23 genes or microRNAs were studied in the relationship between methylation and tumor metastasis. The genes include metastatic genes, metastasis suppressor genes, EMT-related genes, microRNAs and noncoding RNA. The methylation rate of these genes and tumor metastasis were studied. Genes with intensive research include P16, Rassf1, DAPK, HOXA5, SOX9, MALAT1 and microRNAs such as mir-182, mir-139. mir-224. No further studies were regarded in the prediction value of these markers in serum and CTC in lung cancer metastasis. These markers might be validated in metastasis prediction in further studies. Conclusion: Our analysis results reveal that methylation might be associated with tumor metastasis and poor prognosis in NSCLC patients, and might be good markers in liquid biopsy for early detection of lung cancer metastasis. Background: The clinical effect of gefitinib on patients with EGFR mutational advanced non-small cell lung cancer (NSCLC) was remarkable, but was inevitably impaired by progressive drug resistance, and the median time to progression is about 1 year. When complete resection of residual disease is possible, the patients can then be considered disease free before drug-resistant. We have aggressively performed salvage lobectomy for patients with gefitinib responses and demonstrated down-staging to under IIIA stage. The purpose of this study was to evaluate the perioperative safety and survival benefit of the combined treatment. Method: A total of 19 advanced NSCLC patients undergoing surgery after gefitinib treatment were collected from 2016.06 to 2018.06. Among them, 9 cases were IIIB stage, 2 cases were IIIC stage and 8 cases were Ⅳ stage, according to The 8 th Edition UICC Lung Cancer TNM Staging Criteria. All of the 19 patients would make PET/CT scan and assess the clinical stage down-staging to under IIIA stage after treating by gefitinib for from 2-6 months. Then all patients were undergoing video-assisted thoracoscopic
